Health AI Central
Share:
Peer-Reviewed Publication
MAbs2024;16(1):2341443.January 1, 2024Journal Article

Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions.

Michael Mullin1, James McClory1, Winston Haynes1, Justin Grace1, Nathan Robertson1, Gino van Heeke
1LabGenius, London, UK.
PubMed PMC DOI PDF

Abstract

The development of bispecific antibodies that bind at least two different targets relies on bringing together multiple binding domains with different binding properties and biophysical characteristics to produce a drug-like therapeutic. These building blocks play an important role in the overall quality of the molecule and can influence many important aspects from potency and specificity to stabil…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.